KRAS and neoplasm: However, the appliable testing strategy heavily depends on the tumor stage and entity, as for example the mutational spectrum of pancreatic cancer is very homogenous, with >90% of patients harboring KRAS mutations in tissue (eventually no need for prior tissue testing), while the mutational spectrum of colorectal and gastroesophageal cancer is very heterogenous [15].